TB006 is a monoclonal antibody targeting GAL-3, developed by TrueBinding, a new therapeutic approach for neurogenerative diseases.
TB006 reduces neuroinflammation to help damage and restore cognitive function, with minimal side effects.
Inflammation is one of the primary causes of Alzheimer’s disease, and lowering inflammation can help protect the brain and reduce the risk of Alzheimer disease. By lowering inflammation, one of the major risk factors of Alzheimer disease, TB006 is able to help protect the brain, potentially help slow down or even stop the progression of dementia, and help improve memory.
Its first function is to be a first responder, calling on the immune system to rescue damaged cells. In the right amounts, GAL-3 aides in healing. In addition, it frequently gets overproduced and creates a negative feedback loop associated with many chronic diseases.
Excess GAL-3 in the brain disrupts the immune system, rendering the immune system partially to totally dysfunctional, damaging our brain, and causing dementia of all types and severities.
In scientific terms, GAL-3 contributes to forming toxic oligomers and plaques, disrupting communication between neurons and leading to cognitive decline. GAL-3 overactivation triggers excessive microglial activity and chronic neuroinflammation, further damaging neurons.
TB006 neutralizes GAL-3 and allows the immune system to revitalize and heal the brain, thereby enabling the promotion of improved levels of cognition and other brain functions for individuals.
Early clinical trials show promising results for treating various dementias, including:
Vascular dementia
Frontotemporal dementia
Lewy Body dementia
Dementia with mixed pathology
While there are FDA-approved drugs on the market for the treatment of Alzheimer’s Disease, these drugs are only able to slow the progression of Alzheimer’s Disease, and come with serious unwanted side effects.
Specifically, leading Alzheimer’s drugs, Lequimbi and Kisunla, all show signs of disease slowing after 18 months, but none show signs of disease reversal like TB006. And all three drugs showed ARIA side effects at greater rate than would be expected in normal aging Alzheimer’s patients, compared to no ARIA side effects in TB006 patients.
ARIA = Amyloid Related Imaging Abnormalities. Brain bleeds and brain swelling seen on Brain CT or Brain MRI. Monthly imaging is required for Lequimbi and Kisunla, but not for TB006.
Thus far, TB006 has demonstrated to be safe. TB006 is very selective. Very few medications are contraindicated and its singular selectivity permits it to avoid metabolic interaction. This significantly contributes to its high safety profile. TB006 is administered by an IV drip. In a study of 72 people, only 4 people reported minimal side-effects.
The side effects were:
These are common side-effects for any IV administration.
Patients must qualify for the expanded access program and meet certain requirements.
We may be able to help you find a physician offering this program.
